Clinical outcome and safety of periodic infliximab therapy in children and adolescents with crohn’s disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 39, Issue 3, 2004, Pages 302-303

  Diamanti, Antonella ^a   Papadatou, Bronislava ^a   Knafelz, Daniela ^a   Gambarara, Manuela ^a   Ferretti, Francesca ^a   Castro, Massimo ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY;

CROHN DISEASE; HUMAN; INFUSION; NOTE; SAFETY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; INFUSIONS, PARENTERAL; SAFETY; TREATMENT OUTCOME;

EID: 16644378051     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-200409000-00018     Document Type: Letter

References (9)

1. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn’s disease. J Ped Gastroenterol Nutr 2003;36:632-6.
2. Diamanti A, Castro M, Papadatou B, Ferretti F, Gambarara M, Ferretti F. Severe anaphylactic reaction to infliximab in padiatric patients with Crohn’s disease. J Pediatr 2002;140:536.
3. Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Complications of infliximab Therapy in children and adolescents affected by Crohn’s disease. Am J Gastroenterol 2003;98:2812-3.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT 1 randomised trial. Lancet 2002;342:174-5.
5. Hyams JS, Markowitz J, Wyllie R. Use of Infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2001;137:192-6.
6. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to Infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000;95:3189-94.
7. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN, Mannick EE. Use of Infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
8. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano R. Safety and steroid- sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
9. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 2003;18:425-31.